Key result
Percutaneous closure of ostium secundum atrial septal defects using the Memopart™ device achieved 100% total occlusion before hospital discharge with no deaths or complications.
Observational (n=21)
Percutaneous closure of secundum ASD using the Memopart device is safe and achieves a high rate of immediate and sustained occlusion.
Answers are grounded in this paper and cite their sources.
Supports Memopart device feasibility for secundum ASD closure; hypothesis-generating and requires randomized trials before practice change.
The authors report their initial experience with the Memopart™ device (Shanghai Shape Memory Alloy Co Ltd, Shanghai, China) for the occlusion of secundum atrial septal defect (ASD). This was a prospective observational study of a series of patients undergoing percutaneous occlusion of ASD with right ventricle volume overload and favorable anatomic characteristics. The procedure was performed by percutaneous femoral approach. The mean follow-up was 10.3 ± 5 months, with clinical and 24-hour echocardiographic evaluations (or before hospital discharge), 1, 3, 6, and 12 months after implantation. From February/2012 to April/2013, 21 patients, 16 females, mean age 33.1 ± 18.7 years, were submitted to percutaneous occlusion of an ASD. The average diameter of the defect was 19.04 ± 6.25 mm and the device size was 21.42 ± 6.73 mm (8 to 34 mm). Total occlusion of the defect was observed in all cases before hospital discharge. During follow-up, all patients were asymptomatic and without residual shunt. There was no deaths or any other complications in the series. The percutaneous closure of ASD using a Memopart™ device is an effective and safe procedure within the limits of this investigation. The device is user-friendly and has a high rate of immediate occlusion, even in large defects. Oclusão Percutânea de Comunicação Interatrial Tipo Ostium Secundum com Prótese Memopart® Os autores relatam a experiência inicial da oclusão da comunicação interatrial ostium secundum (CIA) com a utilização da prótese Memopart® (Shanghai Shape Memory Alloy Co Ltd, Shanghai, China). Estudo prospectivo observacional, no qual uma série de pacientes portadores de defeitos com significativa repercussão hemodinâmica e características anatômicas favoráveis ao implante foi submetida à oclusão percutânea de CIA. O procedimento foi realizado por via femoral percutânea, pela técnica habitual. O período de seguimento foi de 10,3 ± 5 meses, com controles clínicos e ecocardiográficos 24 horas (ou antes da alta hospitalar), 1, 3, 6 e 12 meses após o implante. No período de fevereiro de 2012 a abril de 2013, foram submetidos à oclusão percutânea de CIA 21 pacientes, sendo 16 do sexo feminino, com idade média de 33,1 ± 18,7 anos. O diâmetro médio do defeito foi de 19,04 ± 6,25 mm e o tamanho da prótese foi de 21,42 ± 6,73 mm (8 a 34 mm). O implante foi realizado com êxito em todos os casos, verificando-se oclusão total no controle antes da alta hospitalar. No seguimento, todos os pacientes estiveram assintomáticos e comprovou-se a persistência da oclusão total do defeito. Não houve mortalidade e nem outras complicações na série. A oclusão percutânea da CIA utilizando-se prótese Memopart® é um procedimento eficaz e seguro, dentro dos limites desta investigação. O implante da prótese é simples e apresenta alto índice de oclusão imediata, inclusive de defeitos de grandes dimensões.
No takes yet. Share an insight, caveat, or question.
Haddad et al. (2013) conducted an observational in Ostium secundum atrial septal defect (ASD) (n=21). Memopart™ occlusion device was evaluated on Total occlusion of the defect before hospital discharge. Percutaneous closure of ostium secundum atrial septal defects using the Memopart™ device achieved 100% total occlusion before hospital discharge with no deaths or complications.
Synapse has enriched 10 related papers. Consider them for comparative context: